#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	18032	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2639	842.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1779	1779	C	1094	C	1094	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	18032	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2639	842.2	0	HET	.	.	.	G1158A	.	1158	1158	G	1753	1753	G	1064	G,A	793,271	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30304	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3991	946.1	0	.	n	.	0	T695C	SNP	695	695	T	1258	1258	C	1166	C,T,G,A	1162,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30304	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3991	946.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1900	1900	A	1238	A,G,C	1234,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30304	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3991	946.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2534	2534	C	1093	C,T,A	1091,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30304	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3991	946.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3160	3160	T	1049	T,C,G	813,235,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30304	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3991	946.1	0	.	n	.	0	G2872A	SNP	2872	2872	G	3435	3435	A	1080	A,G	810,270	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30304	23S	2890	2890	99.83	23S.l15.c4.ctg.1	3991	946.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2608	2608	A	946	A	946	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2550	folP	852	852	100.0	folP.l15.c4.ctg.1	2116	150.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1241	1243	AGC	256;258;259	A;G;C	256;258;259	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6290	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3861	203.1	1	SNP	p	S91F	0	.	.	271	273	TCC	818	820	TCC	261;262;259	T;C;C,A	261;262;258,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6290	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3861	203.1	1	SNP	p	D95G	0	.	.	283	285	GAC	830	832	GAC	260;259;255	G;A;C,A	260;259;254,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6290	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3861	203.1	1	SNP	p	D95N	0	.	.	283	285	GAC	830	832	GAC	260;259;255	G;A;C,A	260;259;254,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	2504	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1748	178.3	1	SNP	p	G45D	1	.	.	133	135	GAC	680	682	GAC	288;286;287	G;A,C;C,T	288;285,1;286,1	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1384	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1393	123.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3433	230.9	1	SNP	p	D86N	0	.	.	256	258	GAC	861	863	GAC	293;294;292	G;A;C	293;294;292	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3433	230.9	1	SNP	p	S87W	0	.	.	259	261	AGT	864	866	AGT	292;293;291	A,G;G;T,G,A	291,1;293;289,1,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3433	230.9	1	SNP	p	S87I	0	.	.	259	261	AGT	864	866	AGT	292;293;291	A,G;G;T,G,A	291,1;293;289,1,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3433	230.9	1	SNP	p	S87R	0	.	.	259	261	AGT	864	866	AGT	292;293;291	A,G;G;T,G,A	291,1;293;289,1,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3433	230.9	1	SNP	p	S88P	0	.	.	262	264	TCC	867	869	TCC	296;300;299	T;C;C,G	296;300;298,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5346	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3198	208.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1809	1811	GGC	293;292;292	G,T;G;C,G	292,1;292;291,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1538	1540	GCA	280;282;284	G,T,C;C,T,A;A	277,2,1;278,2,2;284	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1541	1543	ATC	282;282;282	A;T;C	282;282;282	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1553	1555	GTG	278;277;278	G;T;G,T	278;277;277,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1553	1555	GTG	278;277;278	G;T;G,T	278;277;277,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2057	2059	ACC	286;285;285	A;C,A;C,T	286;284,1;284,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2111	2113	GCG	264;266;265	G;C,T;G	264;265,1;265	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2111	2113	GCG	264;266;265	G;C,T;G	264;265,1;265	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2234	2236	GGC	269;272;274	G;G;C,T	269;272;273,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2243	2245	GGC	273;270;274	G,C;G;C	272,1;270;274	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4864	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2979	203.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2261	2263	CCG	275;279;275	C,G,A;C;G,T,C,A	271,3,1;279;272,1,1,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6760	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3544	237.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3166	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2311	170.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	805	805	C	230	C,T,A	228,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	655	657	GGA	279;280;280	G;G;A,T	279;280;279,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	V75I	NONSYN	223	225	GTT	736	738	ATT	258;258;258	A;T;T	258;258;258	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	778	780	AGC	275;274;274	A;G;C	275;274;274	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	V98I	NONSYN	292	294	GTC	805	807	ATC	261;261;256	A;T;C	261;261;256	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	870	871	CG	233;233	C;G	233;233	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	873	875	CAG	230;226;227	C;A;G	230;226;227	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	877	879	AAA	224;225;226	A;A;A	224;225;226	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	904	906	TAT	239;238;235	T;A;T,G	239;238;233,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	N134E	NONSYN	400	402	AAT	913	915	GAG	247;245;246	G;A;G	247;245;246	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	V135L	NONSYN	403	405	GTG	916	918	CTT	247;247;249	C,T;T;T,G	246,1;247;247,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	G140K	NONSYN	418	420	GGA	931	933	AAA	256;261;258	A;A;A	256;261;258	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	940	942	GAA	256;258;256	G;A,T;A,C	256;257,1;255,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	964	966	GCA	258;258;260	G,C;C;A,G,C	257,1;258;258,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1150	1152	TCA	288;290;293	T,G;C,T;A	287,1;289,1;293	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1270	1272	CAA	212;210;205	C;A;A	212;210;205	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	.	INDELS	760	761	AC	1274	1277	ATCG	206;202;199;195	A;T,G;C;G	206;201,1;199;195	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	.	INDELS	763	764	TG	1280	1283	TAGT	194;189;187;185	T;A;G;T,C	194;189;187;184,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1288	1290	GAT	192;194;196	G;A;T	192;194;196	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1396	1398	AGT	288;293;294	A;G;T	288;293;294	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1402	1404	GAC	307;308;309	G;A;C	307;308;309	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1405	1407	TAC	311;313;316	T;A;C,T,A	311;313;314,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	1	SNP	p	G120K	1	.	.	358	360	AAG	870	872	CGG	233;233;228	C;G;G	233;233;228	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	1	SNP	p	A121D	1	.	.	361	363	GAC	873	876	CGC	230;227;224	C;G;C	230;227;224	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3136	porB1b	1041	1041	96.47	porB1b.l15.c17.ctg.1	1805	215.8	1	SNP	p	D121N	0	.	.	361	363	GAC	873	876	CGC	230;227;224	C;G;C	230;227;224	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	163	93.87	porB3.l15.c17.ctg.3	165	65.9	0	.	p	.	0	S273T	NONSYN	817	819	TCG	62	64	ACT	87;87;87	A;C;T	87;87;87	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	163	93.87	porB3.l15.c17.ctg.3	165	65.9	0	.	p	.	0	D276S	NONSYN	826	828	GAT	71	73	AGT	87;87;87	A;G;T	87;87;87	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	163	93.87	porB3.l15.c17.ctg.3	165	65.9	0	.	p	.	0	K278D	NONSYN	832	834	AAA	77	79	GAC	87;87;87	G;A;C	87;87;87	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	163	93.87	porB3.l15.c17.ctg.3	165	65.9	0	.	p	.	0	R279Y	NONSYN	835	837	CGC	80	82	TAC	87;87;87	T;A;C,A	87;87;86,1	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11766	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5409	271.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2219	2221	AAT	317;319;316	A;A,C;T	317;317,2;316	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1804	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1431	157.1	1	SNP	p	V57M	1	.	.	169	171	ATG	732	734	ATG	303;302;303	A;T;G	303;302;303	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
